Today, 5th October, Audentes announced that continued positive results have been achieved in ASPIRO – the Phase 1/2 clinical trial of AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM). You can read the full press release here.

Furthermore, the attached Patient Letter (in English) represents Audentes’ commitment to open communication to help answer some of the questions that the patient community may have. Other translations are available below.

Audentes Therapeutics remind us that they cannot make any conclusions on the interim findings of the clinical trial until after all enrolled subjects are dosed and evaluated for the duration of the study, and the full scope of the data is collected and analyzed. After all enrolled subjects are dosed and evaluated for the duration of the study, and the full scope of data is collected and analyzed, more complete information about the safety and efficacy of this investigational gene therapy product will become available to the community.

XLMTM Patient Letter 05OCT2018 in Polish

XLMTM Patient Letter 05OCT2018 in Italian

XLMTM Patient Letter 05OCT2018 in French

XLMTM Patient Letter 05OCT2018 in Spanish

XLMTM Patient Letter 05OCT2018 in German